Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Rises By 5.6%

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 3,770,000 shares, an increase of 5.6% from the November 15th total of 3,570,000 shares. Based on an average daily volume of 587,700 shares, the short-interest ratio is currently 6.4 days.

Ascendis Pharma A/S Stock Performance

ASND stock traded up $6.73 during midday trading on Monday, reaching $136.60. 473,154 shares of the company traded hands, compared to its average volume of 449,109. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00. The business has a 50 day moving average of $129.15 and a 200-day moving average of $132.72. The firm has a market capitalization of $8.28 billion, a price-to-earnings ratio of -16.52 and a beta of 0.67.

Analyst Ratings Changes

Several research analysts have recently weighed in on ASND shares. Wedbush reiterated an "outperform" rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Bank of America boosted their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a "buy" rating in a research report on Monday, September 23rd. TD Cowen dropped their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. The Goldman Sachs Group increased their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a "buy" rating in a research report on Tuesday, September 17th. Finally, StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S presently has an average rating of "Moderate Buy" and a consensus price target of $191.77.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Westfield Capital Management Co. LP raised its position in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock worth $766,523,000 after acquiring an additional 170,942 shares during the period. Avoro Capital Advisors LLC lifted its stake in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock worth $572,341,000 after acquiring an additional 229,995 shares in the last quarter. Janus Henderson Group PLC grew its stake in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock worth $625,075,000 after purchasing an additional 267,881 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock worth $278,760,000 after buying an additional 155,971 shares during the period. Finally, Groupama Asset Managment acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.